Products for Research Use Only

BMS-813160

CAT: 0804-HY-109593-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-109593-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BMS-813160 is a potent and selective CCR2/5 dual antagonist. BMS-813160 binds with CCR2 and CCR5 with IC50s of 6.2 and 3.6 nM, respectively. BMS-813160 can be used for the research of inflammation[1][2].
CAS Number
1286279-29-5
UNSPSC
12352005
Hazard Statement
H315, H317, H318, H334, H335, H341, H361, H370, H413
Target
CCR
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Endocrinology; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/BMS-813160.html
Purity
99.82
Solubility
DMSO : 25 mg/mL (ultrasonic; warming) |Ethanol : 100 mg/mL (ultrasonic)
Smiles
CC(N[C@H]1[C@@H](N2C([C@@H](NC3=NC=NC4=CC(C(C)(C)C)=NN43)CC2)=O)CC[C@@H](NC(C)(C)C)C1)=O
Molecular Formula
C25H40N8O2
Molecular Weight
484.64
Precautions
H315, H317, H318, H334, H335, H341, H361, H370, H413
References & Citations
[1]Norman P. et al. A dual CCR2/CCR5 chemokine antagonist, BMS-813160? Evaluation of WO2011046916. Expert Opin Ther Pat. 2011 Dec;21 (12) :1919-24.|[2]Cherney RJ, et al. BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate. ACS Med Chem Lett. 2021 Oct 15;12 (11) :1753-1758.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CCR2; CCR5